Aura Biosciences, Inc.
No SEC Form 4 filings for $AURA in the last 30 days.
Aura Biosciences, Inc. (AURA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001501796 0001501796 2026-08-05 2026-08-05 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5,
31 July 2026 Activities Report for June Quarter 2026 Aura Energy Limited (ASX: AEE, AIM: AURA) ("Aura" or the "Company") is pleased to provide its activities report for the quarter ended 30 June 2026.
Aura Power said North Somerset Council granted planning permission for a 100MW/400MWh, 4-hour BESS in Sandford, with grid connection via existing National Grid infrastructure. The company plans to work with National Grid to advance the connection date amid UK network reforms. Aura also has a 4-hour BESS under construction in Cheshire and targets 1GW RTB solar and storage by 2028.
Over the past 7 days, alphai's AI scored 1 news story mentioning AURA (Aura Biosciences, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent AURA coverage spans financial news, corporate actions and sector analysis.
Authorized-share expansion can increase future dilution capacity, which may pressure valuation until paired with a clear capital plan.
Near-term catalyst is execution progress toward BFS completion and pilot plant commissioning, with funding discussions tied to the finalized flowsheet.
Planning consent is a meaningful de-risking step for Aura’s UK BESS buildout, but the article provides no financial terms or connection-date certainty beyond ongoing grid reform efforts.
Planning approval is a tangible UK permitting milestone that can de-risk development and improve odds of reaching construction and commissioning.
Board appointment is a governance and execution signal, but it does not change bel-sar clinical/regulatory milestones in this release.
alphai scores every news story that mentions AURA with an AI model for sentiment and relevance, and aggregates insider trades from Aura Biosciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Aura Biosciences, Inc. (AURA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001501796 0001501796 2026-08-05 2026-08-05 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5,
2 min read31 July 2026 Activities Report for June Quarter 2026 Aura Energy Limited (ASX: AEE, AIM: AURA) ("Aura" or the "Company") is pleased to provide its activities report for the quarter ended 30 June 2026.
4 min readAura Power said North Somerset Council granted planning permission for a 100MW/400MWh, 4-hour BESS in Sandford, with grid connection via existing National Grid infrastructure. The company plans to work with National Grid to advance the connection date amid UK network reforms. Aura also has a 4-hour BESS under construction in Cheshire and targets 1GW RTB solar and storage by 2028.
4 min readGreentechLead reports renewable-energy updates. Masdar reached financial close on a $6.1B Abu Dhabi 24/7 solar plus battery project, with 5.2 GW PV and 19 GWh storage, targeting 1 GW continuous output. Aura Power received UK planning approval for a 100 MW, four-hour Sandford BESS. NextEnergy’s Starlight got consent for a 240 MW/960 MWh UK BESS.
2 min readAura Biosciences (NASDAQ: AURA) said it appointed Jeremy Bender, Ph.D., M.B.A., to its board of directors. The company noted Bender’s prior leadership at Day One Biopharmaceuticals and experience in oncology development and commercialization. Aura also referenced Phase 3 CoMpass trial enrollment completion and bel-sar’s potential regulatory approval path.
2 min readAura Biosciences, Inc. (AURA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K 0001501796 false 0001501796 2026-07-03 2026-07-03 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2
2 min readBiotech gainers included SL Science (SLBT), up 34.61% to $5.99 after Nasdaq trading began June 15; Chemomab (CMMB), up 33.53% to $2.27 as Phase 3 preparations for Nebokitug in primary sclerosing cholangitis continue; Propanc (PPCB), up 22.92% to $1.77 after a $500k buyback authorization. Also: VERAXA (VRXA) +18.26% to $2.04 with ATUM support; Tectonic (TECX) +15.85% to $37.93 ahead of Phase 2/1 catalysts; Aura (AURA) +15.01% to $7.74 ahead of bel-sar data; SELLAS (SLS) +12.89% to $14.98 with REG
7 min readAura Biosciences, Inc. (AURA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001501796 0001501796 2026-06-11 2026-06-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11,
2 min readBOSTON, Nov. 24, 2025 ( GLOBE NEWSWIRE ) -- Aura Biosciences, Inc. ( NASDAQ: AURA ) , a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will ...
3 min readROCKVILLE, Md., Nov. 20, 2025 ( GLOBE NEWSWIRE ) -- NovaBridge Biosciences ( Nasdaq: NBP ) ( NovaBridge or the Company ) a global biotechnology platform company committed to accelerating access to innovative medicines, today announced that its subsidiary Visara, Inc. ( Visara ) has appointed ...
2 min read
